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Introduction
Hypoxic preconditioning has long been considered as 
organ-protective, and its clinical usage has been 
suggested in elective procedures, such as coronary 
surgery and organ transplantation. Although the mecha-
nisms have not been clearly elucidated, it has been 
postulated that changes in cell-membrane composition 
and upregulation of various cellular protective mecha-
nisms are responsible for a better tolerance of acute 
injury. Remote preconditioning (i.e., hypoxic stress in one 
organ conferring resistance to acute hypoxia in other 
organs) suggests organ cross-talk, perhaps mediated by 
cytokines and the immune system.
Increased expression of heme-oxygenase (HO)-1, heat-
shock proteins (HSP), growth factors such as vascular 
endothelial factor (VEGF), and erythropoietin (EPO) are 
among the numerous adaptive responses to sublethal 
injury that are believed to participate in tissue tolerance 
during subsequent stress. EPO, for instance, is a ubiqui-
tous pleiotropic survival and growth factor that attenu-
ates experimental acute injury in various organ systems, 
including neuronal, retinal, cardiac, renal, and hepatic 
tissues. Its clinical eﬃ   cacy, though suggested in critically 
ill patients, is yet to be deﬁ  ned [1].
Th   e expression of these protective mediators and many 
others is regulated by hypoxia-sensing mechanisms 
through the induction and stabilization of so called 
hypoxia-inducible factors (HIF) [2]. In this chapter, we 
will outline the control and action of HIF as key regula-
tors of hypoxic adaptive response, and particularly 
examine HIF expression during hypoxic stress. We shall 
discuss recently developed measures that enable HIF 
signal modiﬁ  cation and describe their potential use in 
conferring tissue tolerance during incipient organ injury.
HIF regulation and action
HIFs are heterodimers (Fig. 1), composed of a constitutive 
β-subunit (HIF-β) and one of three diﬀ  erent  oxygen-
dependent and transcriptionally active α-subunits, among 
which HIF-1α and -2α are acknowledged as promo  tors of 
hypoxia adaptation, whereas the role of HIF-3α remains 
unclear. Under normoxia, HIF-α subunits are constantly 
produced, but not allowed to accu  mulate, since they are 
rapidly hydroxylated by oxygen-dependent HIF prolyl-4-
hydroxylase domain enzymes (PHD), subsequently 
captured by the ubiquitin ligase Von-Hippel-Lindau 
protein (VHL), and degraded by the proteasome. Under 
oxygen deﬁ   ciency, PHD activity is reduced, HIF-α 
accumulates within the cytosol, αβ-dimers are formed, 
translocate into the nucleus, and bind to hypoxia 
response elements (HREs) in the promoter enhancer 
region of genes, which are subsequently transactivated 
[2–4].
Th  e biological eﬀ  ects of the more than 100 acknow-
ledged HIF target genes are multiple, and include key 
steps in cell metabolism and survival. Many of the HIF-
target genes constitute a reasonable adaptation to 
hypoxia, such as erythropoiesis (EPO), increased glucose 
uptake (glucose transporter-1), switch of metabolism to 
glycolysis (several key enzymes of glycolysis), increased 
lactate utilization (lactate dehydrogenase), angiogenesis 
(VEGF), vasodilation (inducible nitric oxide synthase 
[iNOS]), removal of protons (carbonic anhydrase 9), and 
scavenging of free radicals (HO-1) [2–4].
Biological and rherapeutic modes of HIF activation
Every cell type has the potential to upregulate HIF, 
principally by the inhibition of PHD, under conditions 
when cellular oxygen demand exceeds oxygen supply, 
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under the German Copyright Law.namely under cellular hypoxia. However, the threshold 
and extent of HIF activation may depend on the hypoxic 
stimulus and cell type involved. To some extent, these 
cellular variations may reﬂ  ect  diﬀ   erent expression of 
various PHD isoforms in diﬀ  erent tissues [5–7].
As HIF stimulation may potentiate hypoxia tolerance, 
studies were conducted to explore its clinical application. 
Widespread experimental hypoxic stimuli are listed in 
Table  1, all acting principally by the control of HIF-α 
degra  dation, initiated by PHDs. Except for carbon 
monoxide exposure, which is currently being tested in 
patients, none of these stimuli seems suitable for 
preconditional HIF activation in humans.
Apart from hypoxic stabilization, widely proven in vivo, 
HIF activation has also been demonstrated to occur 
under normal ambient oxygen tensions, mostly in cell 
cultures challenged with cytokines and growth factors. 
However, under stress, oxygen demand likely is increased, 
thus possibly leading to intracellular hypoxia even in cells 
kept under room air. For technical reasons, it is probably 
impossible to rule out such local cellular hypoxia that 
may exist predominantly within the mitochondria. 
Beyond this academic distinction between true cellular 
hypoxia and normoxia, it is important to recognize that 
clinical conditions, like inﬂ   ammation, infection and 
sepsis, may lead to HIF activation. Th  us, theoretically, 
cytokines or growth factors could be used for precon-
ditional HIF activation in humans.
Although not a reasonable therapeutic intervention, 
strong and stable normoxic HIF activation can be 
Figure 1. A schematic display of hypoxia-inducible factor (HIF) regulation and biological action. Prolyl-4 hydroxylases (PHDs) serve as 
oxygen sensors and under normoxic conditions promote degradation of HIF-α isoforms in the proteasome following binding with the ubiquitin 
ligase, Von-Hippel-Lindau protein (VHL). Hypoxia inhibits PHDs and leads to HIF-α accumulation with HIF-β, and the αβ heterodimer translocates 
into the nucleus, binds with hypoxia-response elements (HRE) and activates numerous genes important in cell metabolism, proliferation and 
survival. Many of these genes play a central role in injury tolerance and promotion of tissue oxygenation, such as erythropoietin (EPO), vascular 
endothelial growth factor (VEGF), inducible NO synthase (iNOS), heme oxygenase (HO)-1, glucose transporter-1, or carbonic anhydrase (CA)-9. 
Underscored is the inactivation of the HIF-HRE axis by hypoxia, which can be mimicked by carbon monoxide (functional anemia) or by transition 
metals like cobaltous chloride. Hypoxia-mimetic PHD inhibitors (PHD-I) are potent newly developed measures in the induction of the HIF-HRE 
axis. For simplicity, numerous additional factors involved in HIF regulation and action are not included in this cartoon and the reader is referred to 
comprehensive reviews such as references [3, 12].
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Page 2 of 7achieved by deletion of the VHL gene, which is a constant 
phenomenon in Von Hippel Lindau Disease and in renal 
clear cell carcinoma, and is also encountered in other 
tumors. Transgenic animals with VHL knockout serve to 
test the potential of HIF activation in ischemic/hypoxic 
diseases (C Rosenberger, unpublished data) [8]. Addi-
tional experimental probes for enhancing HIF signal are 
by transfection with PHD siRNA [9] or with the genera-
tion of constitutively active HIF-α transgenes [10].
So-called hypoxia mimetics block PHD activity, thus 
upregulating HIF under normoxia. PHDs require 
2-oxoglutarate and ferrous iron as co-substrates. Non-
speciﬁ   c PHD inhibitors are either 2-oxoglutarate ana-
logues or interfere with Fe2+. Recently, more speciﬁ  c PHD 
inhibitors (PHD) have been synthesized [11], and are 
currently being tested in animal and human studies.
Figure 1 represents a simplistic scheme of the canonical 
HIF regulation and action. Recent discoveries underscore 
a host of additional compound biological pathways, 
associated with the regulation of the HIF signal, including 
the control of HIF synthesis, HIF controlling PHD syn-
thesis, putative competing/intervening impacts of HIF-3α 
and PHD-3, cross-talk of HIF and other key regulators of 
gene expression (STAT, p-300 and others), further 
modiﬁ  cation of HIF-α activity at the level of DNA hypoxia-
responsive elements by small ubiquitin-like modiﬁ  ers 
(SUMO) and factor inhibiting HIF (FIH), and the eﬀ  ect of 
reactive oxygen species (ROS), NO and Krebs cycle 
metabolites on HIF degradation. Th   ese complex pathways 
are beyond the scope of this review, and the interested 
reader is referred to additional references [3,5,12–18].
HIF expression under hypoxic stress and tissue 
injury
Th  e kidney serves as an excellent example for under-
standing HIF expression under hypoxic stress. Renal 
oxygenation is very heterogeneous, with PO2 falling to 
levels as low as 25 mmHg in the outer medulla under 
normal physiologic conditions and to even lower values 
in the papilla [3,4,19]. Changes in renal parenchymal 
microcirculation and oxygenation have been thoroughly 
investigated in acute and chronic renal disorders [19,20]. 
Finally, the complex renal anatomy in which diﬀ  erent cell 
types are in close proximity to regions with comparable 
ambient oxygenation, enables comparisons of cellular 
HIF response.
Interestingly, HIF expression is below detection thresh-
old by immunostaining in the renal medulla, despite low 
physiologic ambient oxygenation (It should be empha-
sized that this statement regarding negative HIF 
immuno  staining in the normally hypoxic medulla relates 
to kidneys perfusion-ﬁ  xed in vivo without an interruption 
of renal oxygenation before ﬁ   xation. Other modes of 
tissue harvesting for HIF determination, either by 
immunostaining or by molecular biology techniques may 
be falsely positive, as hypoxia-induced inhibition of PHD 
activity is instantaneous, and may lead to HIF-α stabili-
zation even over short periods of hypoxia). Conceivably, 
this reﬂ  ects the plasticity of HIF control to adjust for 
‘physiologically normal’ oxygenation (i.e., adjusted rates 
of HIF-α generation and degradation under normal 
conditions.
Enhanced renal HIF-α is noted in rodents subjected to 
hypoxia or to inhaled carbon monoxide (chemical 
hypoxia) [21], and in hypoxic isolated perfused kidneys 
[22]. Diﬀ  erent cells express diverse HIF isoforms: Where  as 
tubular segments express HIF-1α, HIF-2α is principally 
produced by vascular endothelial and interstitial cells 
[21–23]. Interestingly, HIF-dependent genes are also 
selectively expressed in diﬀ  erent cell types. For instance 
HIF-2-triggered EPO generation is speciﬁ  cally found in 
interstitial cells in the deep cortex [24]. In hypoxic 
Table 1. Modes of HIF signal enhancement
Stimulus/Agent  Remarks  Potential Clinical Applications
Inhibition of PHDs by the induction of cellular physiologic hypoxia
  Hypoxic chamber (e.g., 8% O2 in ambient air)  depressed systemic PO2  
  Carbon monoxide admixture to ambient air  functional anemia normal systemic PO2  
 Anemia    normal systemic PO2
  Arterial clamping    normal systemic PO2
Chemical inhibition of PHDs by hypoxia-mimetics
 CoCl2 (interferes with Fe2+) non-specifi   c 
  Mimosine (2-oxoglutarate analogue)  non-specifi  c 
  Other patented PHD inhibitors  specifi  c  
Molecular biology techniques
 Von-Hippel-Lindau  knockout  non-specifi   c 
  PHD siRNA transfection  PHD-specifi  c  
  Constitutively active HIF-α transgenes  organ-specifi  c  
PHD: prolyl hydroxylase domain enzyme
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lary hypoxia by the inhibition of tubular transport 
markedly enhanced HIF expression, probably under-
scoring a window of opportunity to generate HIF and 
HIF-mediated adaptive responses only under moderate 
and sublethal hypoxic stress [22]. Th   is pattern is 
consistent with HIF expression at the border of renal 
infarct zones only, indicating that dying cells within the 
critically ischemic region are incapable of mounting a 
hypoxia adaptive response [25].
We also found that HIF-α isoforms are stabilized in 
acute hypoxic stress, predominantly in the cortex in 
rhabdomyolysis-induced kidney injury [26], in the outer 
stripe of the outer medulla following ischemia and reper-
fusion [27,28], or in the inner stripe and inner medulla 
following the induction of distal tubular hypoxic injury 
by radiocontrast agent, or after the inhibition of 
prostaglandin or NO synthesis or with their combinations 
[23]. Outer medullary HIF stabilization is also noted in 
chronic tubulointerstitial disease [29] and in experi  men-
tal diabetes [30], again spatially distributed in areas with 
proven hypoxia. HIF was also detected in biopsies from 
transplanted kidneys [31]. Th   us, HIF immunostaining is 
chronologically and spatially distributed in renal regions 
with abnormally low PO2.
Normal mice subjected to warm ischemia and reper-
fusion display limited injury only, as compared with 
extensive damage in HIF (+/-) mice [32]. Th  us, the 
impor  tance of mounting an HIF response during hypoxic 
stress is undeniable.
Hypoxia-driven HIF stabilization during hypoxic stress 
has been encountered in other organs as well. HIF-1α 
and PHD-2 expression increased in the neonatal rat brain 
following hypoxia [33] and HIF was detected in the 
hypoxic subendocardium [34] and in the ischemic liver 
[27]. HIF is also found within hypoxic regions in tumors, 
and may play an important role in tumor progression via 
upregulation of growth promoting and angiogenic factors 
[35].
Potential usage of HIF modulation in clinical 
practice
Th   e impact of HIF stimulation on the expression of HIF-
dependent tissue-protective genes led to the expectation 
that timely upstream HIF stimulation may have great 
potential in the protection of endangered organs by 
down  stream induction of protective genes [12]. Indeed, 
repeated systemic hypoxia, for instance, results in 
enhanced expression of renal HIF and HIF-dependent 
genes and attenuates warm-ischemic injury [36].
Th  e use of hypoxia-mimetic PHD inhibitors is a 
promis  ing potential new treatment option in diseases 
such as myocardial infarction, stroke, renal or liver injury, 
peripheral vascular disease, or severe anemia. Studies 
with PHD inhibitors and other manipulations of HIF 
upregulation favor this hypothesis [11].
Anemia
Speciﬁ   c PHD inhibitors induce HIF-2α expression in 
interstitial ﬁ  broblasts in the deep cortex [24], enhance 
erythropoietin generation, and were found to provoke 
erythrocytosis in primates [37]. Phase 2 clinical trials in 
patients with chronic kidney disease are currently under 
way, studying the eﬀ   ect of oral PHD inhibitors as 
potential substitutes to EPO injection.
Acute kidney injury
Th  e potential protective impact of HIF upregulation by 
PHD inhibitors has been extensively studied in acute 
kidney injury. In isolated kidneys perfused with low-
oxygen containing medium, pre-treatment with a PHD 
inhibitor improved renal blood ﬂ   ow and attenuated 
medullary hypoxic damage [38]. Conditional inactivation 
of VHL in mice (hence HIF stabilization) resulted in 
tolerance to renal ischemia and reperfusion [8] and to 
rhabdomyolysis-induced acute kidney injury (Rosen-
berger C, unpublished data). Whereas gene trans  fer of 
negative-dominant HIF led to severe damage in the 
normally hypoxic renal medulla in intact rats, transfer of 
constitutively active HIF (HIF/VP16) induced expression 
of various HIF-regulated genes and protected the 
medulla against acute ischemic insults [39]. Furthermore, 
in rats and mice subjected to warm ischemia and reﬂ  ow, 
PHD inhibitors and carbon monoxide pre-treatment (i.e., 
functional anemia) markedly attenuated kidney damage 
and dysfunction [32,40]. Donor pre-treatment with a 
PHD inhibitor also prevented graft injury and prolonged 
survival in an allogenic kidney transplant model in rats 
[41]. Finally, rats preconditioned by carbon monoxide, 
displayed reduced cisplatin renal toxicity, with 
attenuation of renal dysfunction and the extent of tubular 
apoptosis and necrosis [42]. Taken together, all these 
observations indicate that HIF stabilization seemingly is 
a promising novel interventional strategy in acute kidney 
injuries [12].
Myocardial injury
Activation of the HIF system has also been found to be 
cardioprotective. In a model of myocardial ischemia in 
rabbits, pre-treatment with a PHD inhibitor induced 
robust expression of HO-1 and markedly attenuated 
infarct size and myocardial inﬂ  ammation [43]. In another 
report, PHD inhibitors did not reduce infarct size, but 
improved left ventricular function and prevented 
remodeling [44]. In the same fashion, selective silencing 
of PHD-2 with siRNA 24  h before global myocardial 
ischemia/reperfusion in mice reduced the infarct size by 
70% and markedly improved left ventricular systolic 
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renal artery occlusion also resulted in cardiac protection, 
conceivably through PHD inhibition [45].
Enhanced levels of PHD-3 were traced in the 
hibernating myocardium [34] and in end-stage heart 
failure in humans, associated also with elevated HIF-3α 
[46] (which may act as a competitive inhibitor of active 
HIF-α isoforms [14]). Th   us, PHD inhibitors may 
conceivably also be beneﬁ  cial in these disorders. Finally, 
cardioprotection during heat acclimation is also 
mediated in part by HIF upregulation [47], providing 
another potential situation for the administration of PHD 
inhibitors.
Neuronal injuries
Th  e eﬀ  ect of PHD inhibitors has also been assessed in 
disorders of the central nervous system. In vitro, rotenone-
induced neuronal apoptosis was attenuated and auto-
phagy increased, as the result of enhanced HIF following 
deferoxamine administration [48]. In vivo, PHD inhibi-
tors have shown promising results in the attenuation of 
ischemic stroke [49], and might be neuroprotective in 
metabolic chronic neurodegenerative conditions [50]. 
However, studies showing inhibition of PHD-1 by ROS 
suggest non-HIF-mediated neuronal protection under 
normoxic conditions [51].
Lung injury
Preterm lambs developing respiratory distress syndrome 
display upregulation of PHDs with a reciprocal fall in 
HIF-α isoforms and HIF-dependent VEGF [53]. Th  is 
observation implies that PHD inhibitors might have 
therapeutic potential in this clinical setup.
Liver disease
Hepatic HIF-1α is upregulated following warm ischemia 
[27], and is required for restoration of gluconeogenesis in 
the regenerating liver [52], implying yet another potential 
use for PHD inhibitors in acute liver disease.
Peripheral vascular disease
In a model of limb ischemia in mice, PHD inhibitors 
enhanced HIF expression and downstream VEGF and 
VEGF-receptor Flk-1, leading to improved capillary 
density, indicating a potential therapeutic use of PHD 
inhibi  tors in promoting angiogenesis in ischemic 
diseases, such as severe peripheral vascular disease [54]. 
Transfection with HIF-1α, combined with PHD inhibitor-
treated bone marrow-derived angiogenic cells increased 
perfusion, motor function, and limb salvage in old mice 
with ischemic hind limbs [55]. Results of a phase-1 study 
in patients with critical limb ischemia indicate that 
transfection with a constitutively active form of HIF-1α 
might also promote limb salvage [10]. Further clinical 
trials with PHD inhibitors are currently under way in 
burn wound healing and salvage of critically ischemic 
limbs.
Oxidative stress
Enhanced cellular ROS concentrations, as happens with 
shock and tissue hypoxia, result in increased PHD 
activity, and this eﬀ  ect is antagonized by ROS scavengers 
[15]. Th   is situation may lead to HIF de-stabilization and 
inadequate HIF response to hypoxia. For example, 
hypoxia-mediated HIF expression in the diabetic renal 
medulla is substantially improved by the administration 
of the membrane-permeable superoxide dismutase 
mimetic tempol [30]. It is, therefore, tempting to assume 
that ROS scavengers, as well as PHD inhibitors may 
improve tissue adaptive responses to hypoxia, coupled 
with oxidative stress. However, contradicting evidence 
exists, indicating that ROS might trigger HIF in the 
absence of hypoxia. Th   is has been suggested by studying 
liver tissue in acetaminophen-induced liver injury, before 
the development of overt liver injury and hypoxia [56], 
and in aged well-fed animals [57]. Th  e role of HIF 
stimulation during oxidative stress therefore needs 
further assessment.
Important considerations
HIF stimulation is not all-protective. Th  e wide range of 
HIF-dependent genes, and its tight cross-communication 
with other key regulators of gene expression [13,58,59] 
raise concern regarding concomitant non-selective activa-
tion of protective as well as harmful systems. Among poten-
tial unwanted outcomes is the enhancement of tumor 
growth [60], promotion of ﬁ  brosis [61] or the induction 
of pre-eclampsia in pregnant women [62]. Indeed, 
whereas HIF activation is considered renoprotec  tive in 
acute kidney injury, it may play a role in the progression 
of chronic kidney disease and certainly is an important 
factor in the promotion of renal malignancy [3,20].
Diverse characteristics and distribution patterns of 
diﬀ  erent PHDs [5–7] and particular actions of various 
PHD inhibitors [11,37] might enable selective manipu-
lation of the HIF system in a more desired way, selectively 
favoring advantageous HIF-dependent responses in 
preferred tissues. Furthermore, it is believed that activa-
tion of adverse responses requires protracted HIF 
stimulation, whereas short-term and transient HIF 
activa  tion might suﬃ     ce to activate tissue-protective 
systems without continuing induction of harmful 
systems. However, this concept needs conﬁ  rmation  in 
clinical trials.
Conclusion
Elucidating the mechanisms involved in HIF-mediated 
cellular responses to acute hypoxic stress has led to the 
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prevention or attenuation of tissue injury. Th  e  non-selec-
tive enhancement of gene expression by current modes of 
HIF augmentation warrants caution, since undesired 
enhancement of certain genes may be hazardous.
We anticipate that in the coming years the use of PHD 
inhibitors and other stimulants of the HIF system will be 
tested in many clinical scenarios associated with critical 
care and emergency medicine, while HIF silencing 
strategies may be tested in chronic diseases, such as 
malignancies and disorders with enhanced tissue 
scarring.
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